ChromoGenics: First take Q1’23 - Redeye

Redeye states that ChromoGenics Q1’23 report was overall better than expected despite soft top line. Net sales came in at SEK5.8m. This was below our estimates of SEK10m. The reason for the deviation is an absence of new larger orders during the quarter as the downturn in renovation and new construction continues to decline.

Länk till analysen i sin helhet: https://www.redeye.se/research/907863/chromogenics-first-take-q123?utm_source=finwire&utm_medium=RSS